Commercial files identified
47
licensing, buyer, package, rights, or commercial-density hits
Licensing architecture
BioAtlas licensing is a commercial rights architecture, not a download page.
BioAtlas can be packaged by asset family, buyer type, access depth, dataset scope, API or SaaS use, territorial rights, white-label use, AI-rights boundary, or acquisition pathway. Public pages show the commercial map. Protected material requires reviewed access.
Package / bundle signals
1,123
module, package, kit, API, dataset, engine, and tier references
Buyer / market signals
702
clinic, oncology, research, biotech, pharma, enterprise, and institution terms
Rights / IP signals
27
exclusive, territorial, global, royalty, revenue-share, no-AI, and no-derivative terms
BioAtlas public estate map
Open for exploration. Governed for responsible use.
BioAtlas is staged deliberately: public proof, research provenance, platform engines, commercial packaging, protected diligence, and reviewed access. Each layer shows enough for the right audience without exposing protected routes, data-room material, or internal app surfaces.
01Open
Public proof layer
Readable public pages, safe summaries, route maps, DOI links, and the high-level BioAtlas story.
public pagessafe summariesroute map
02Open
Research provenance
DOI-backed papers, preprints, Zenodo records, grouped research collections, and public provenance.
DOI indexpreprintsresearch collections
03Open
Platform engines
QTOS, Rubik, ECS, oncology, microbiome, cell atlas, systems biology, neuro, and infrastructure families.
engine familiesplatform overviewinvestor proof
04Open
Commercial packaging
Licensing families, dataset access, SaaS/API routes, white-label scope, and AI-rights boundaries.
asset familiesrights architecturebuyer routes
05Open
Protected diligence
Buyer review, data-room categories, staged release, provenance, IP boundaries, and technical diligence.
data-room mapbuyer reviewprotected boundaries
06Open
Reviewed access
Serious research, licensing, diligence, platform, API, and acquisition routes start with reviewed access.
access requestAdmin reviewcontrolled release
Education graph licensing
Academy, course, and research navigation can be licensed as a governed training surface.
The current education graph connects 7 Academy tracks,42 modules, 7 course records, and 10 research families across 92 mapped relationships. It packages BioAtlas learning, research orientation, safety boundaries, and reviewed-access routes into a structured navigation layer rather than a loose content library.
Tracks
7
Modules
42
Courses
7
Graph edges
92
Quiz coverage
42/42
Edges / track
13.14
Safety levels
4
Multiomics commercial estate
Source-backed Multiomics scale for commercial review.
Multiomics Intelligence can be packaged as a reviewed licence family covering blueprint architecture, cross-domain reasoning, coverage intelligence, evidence provenance, research bucket structure, and Multiomics-to-illness crosswalk methodology. Public metrics show estate scale only; they are not raw data export rights, AI-ingestion rights, or clinical validation claims.
miRNA registry entries
2,824
Universal targets
3,659
Microbiome crosswalks
1,099
Cell physics profiles
212
Cell-system mappings
211
DNA canonical entities
60
Research bucket families
8
Licence families
Commercial packages are organised by asset family.
The audited business portfolio points to a wide commercial estate: licensing suites, systems oncology intelligence, ECS intelligence, neuro systems, API infrastructure, multiomics intelligence, epigenetic logic, metabolic pathways, microbiome assets, and institutional IP access.
Epigenetic & Histone Intelligence
Epigenetic and histone intelligence packages DNA methylation, histone modification, chromatin remodelling, regulatory RNA, enzyme-epigenetic bridge architecture, hallmark context, nutrigenetic context, and multiomics integration into a reviewed commercial intelligence family.
epigeneticshistoneschromatinDNA methylationenzymesmultiomics
Pathway Intelligence
Pathway Intelligence packages pathway cards, hallmark bridges, enzyme bridges, PCD bridges, cross-domain reasoning, and pathway intelligence methodology into a reviewed commercial intelligence family.
pathwayshallmarksenzymesPCDmultiomics
miRNA Intelligence
miRNA Intelligence packages regulatory RNA context, hallmark bridge architecture, PCD-linked index logic, enzyme-linked regulatory context, compound-linked cross-index orientation, and multiomics integration into a reviewed commercial intelligence family.
miRNAregulatory RNAhallmarksPCD indexenzyme bridgemultiomics
Multiomics Intelligence
Multiomics Intelligence packages genomics, epigenetics, miRNA systems, proteomics, pathway intelligence, enzyme intelligence, microbiome intelligence, cell-state intelligence, illness crosswalks, and systems-level biological navigation into a governed commercial intelligence layer.
genomicsepigeneticsmiRNAproteomicssystems biologycross-domain reasoningprecision medicine
QTOS Systems Architecture
The top-level systems architecture family for QTOS, Rubik, physics-first biology, systems-state interpretation, and infrastructure-grade review pathways.
QTOSRubiksystems enginearchitecture
SaaS & API Infrastructure
White-label, API, institutional, and workflow infrastructure routes for controlled platform evaluation, dataset access, output engines, and integration review.
SaaSAPIwhite-labelinstitutional
Systems Oncology Intelligence
Systems-oncology intelligence covering hallmark mapping, PCD context, subtype intelligence, metabolic adaptation logic, cell-state behaviour, and buyer diligence.
oncologyPCDhallmarksdiligence
ECS Endocannabinoid System Suite
ECS architecture, receptor maps, GPCR signalling, immunometabolism, cannabinoid-context logic, and reviewed systems-translation intelligence.
ECSGPCRimmunometabolismsystems biology
Cell-State Intelligence Systems
Cell-state, surfaceome, immune-cell, stem-cell, neuroimmune, miRNA, and PCD-linked intelligence families for research and commercial review.
cell atlasmiRNAsurfaceomecell fate
Epigenetics & Enzymatic Logic
Histone control, enzyme intelligence, nutrigenetics, pathway logic, and epigenetic-control datasets for biotech, pharma, and research buyers.
enzymesepigeneticsnutrigeneticspathways
Gut & Microbiome Systems Layer
Microbiome, gut-brain-skin, ECS-microbiome, signalling-axis interpretation, and systems-biology packages for research and institutional review.
microbiomegut axissignallingsystems biology
Neuro & Nervous Systems
Neuroimmune pathway datasets, neural regulation, cognitive systems, and nervous-system research assets.
neuroneuroimmunecognitiveneural systems
Commercial enzyme intelligence
A licensable mechanism-intelligence layer
Enzyme intelligence can support professional access, biotech target context, pharma mechanism review, diligence packs, enterprise graph/API rights, and evidence-backed commercial evaluation.
1,724 enzymes
Atlas
38 groups
Families
6 layers
Field model
Rights architecture
Rights expand as extraction power expands.
Licensing discussions should separate what a buyer can view, test, integrate, automate, embed, commercialise, redistribute, train on, derive from, white-label, or acquire. A page view is not a dataset licence, and reviewed access is not an AI-ingestion licence.
view-only evaluationresearch reviewdataset accessengine accessAPI accesswhite-label deploymentterritorial rightsexclusive / non-exclusive rightsglobal or regional scopeannual renewalroyalty or revenue-share termsacquisition pathwayno AI ingestionno derivative databaseno replicationusage boundaries
Buyer routes
Different buyers need different access pathways.
The commercial audit surfaced buyer language across professional groups, oncology, research, biotech, pharma, laboratories, institutions, enterprises, partners, acquirers, manufacturers, distributors, institutional routes, and public-health contexts.
Research and academic review
For researchers, universities, and institutions assessing public records, research families, and selected protected summaries.
Biotech and pharma evaluation
For target-discovery, oncology, gene-editing, enzyme, immunology, microbiome, and platform-integration review.
Clinical and professional review pathway
For reviewed education, safety framing, non-prescriptive systems interpretation, and governed access pathways.
Enterprise and white-label pathway
For SaaS, API, workflow, deployment, institutional platform, and white-label commercial discussions.
Strategic buyer or acquisition route
For staged data-room access, asset-family review, valuation discussion, acquisition screening, and protected technical diligence.
Institutional and public-health route
For large-scale public-health, research-network, institutional, and infrastructure deployment conversations.
Packaging signals
The estate can be packaged as modules, kits, datasets, engines, API access, or institutional deployments.
The audit found strong package and bundle density. Public wording should present this as controlled commercial packaging, not open public download.
packagebundlekittierplanmoduledatasetengineAPIproductcategoryinstitutional
Public catalogue, protected terms
Licence families can be public while commercial terms stay reviewed.
The public licensing page can show asset families, buyer lanes, rights categories, and AI-use boundaries. Pricing, exclusivity, territory, API scope, and commercial terms remain protected.
Public layer
What can be seen publicly
public page summaries
route map and estate map
DOI and preprint links
research collection names
safe paper summaries
licence family names
buyer lane overview
safety and non-claims boundary
access request funnel
Protected layer
What requires review
protected manuscripts
private vault assets
raw datasets and data-room extracts
buyer packs and valuation notes
pricing and commercial terms
technical architecture detail
internal app surfaces
controlled demos
AI-use or derivative-use rights
Public visibility is not a licence. Public pages do not grant access to protected material, commercial terms, AI ingestion, derivative databases, model training, redistribution, replication, or clinical use.
AI-rights boundary
AI ingestion, replication, and derivative use are separate rights.
Reviewing BioAtlas material does not grant permission to ingest it into AI systems, scrape it, vectorise it, train on it, reconstruct the platform, create derivative databases, resell the material, or build a competing system. These rights must be negotiated explicitly.
Research-backed licence families
The DOI trail supports the licence families without turning this page into a research catalogue.
Licensing should be reviewed by asset family, buyer route, rights boundary, and intended use. The records below provide public provenance for each family; detailed terms, pricing, exclusivity, API scope, dataset access, and AI-use rights remain reviewed.
QTOS / Rubik systems infrastructure
Platform architecture, constraint-first computation, reachability boundaries, capability-envelope scope, and infrastructure-grade review.
Buyer fit: Platform buyers, acquirers, technical diligence teams, AI infrastructure reviewers
QTOS systems-state framework — historical DOI title
Public provenance record
A Physics-First Framework for Multi-Layer Disease Dynamics
2025 · Open preprint
QTOS Capability Envelope & System Guardrails (v1.0): Formal Definition of Scope, Limits, and Non-Claims
2025 · Zenodo record
Rubik vs Supercomputers: Constraint-First Computation and Governance Infrastructure
2025 · Zenodo record
Oncology / PCD / systems oncology
Hallmark mapping, programmed cell death datasets, metabolic adaptation logic, ECS signalling context, tumour microenvironment interpretation, and oncology intelligence packaging.
Buyer fit: Pharma, biotech, oncology platforms, diligence reviewers, translational research teams
A Therapeutic Framework Integrating 22 Hallmarks of Cancer with ECS, Bioelectric, and Systems Biology Layers
2025 · Report
ECS PCD Omni Modulation Framework
2025 · Report
Advanced Metabolic Reprogramming
2025 · Report
Systems oncology treatment framework (historical research title)
Public provenance record
ECS / microbiome / systems biology
ECS systems coordination, microbiome integration, mitochondrial bioenergetics, immune coordination, and cross-system intelligence.
Buyer fit: Microbiome companies, ECS researchers, systems-biology groups, institutional reviewers
The Endocannabinoid System as a systems-regulated operating model — historical DOI title
Public provenance record
ECS–microbiome integration: A multi-domain systems biology framework
Public provenance record
ECS & Mitochondrial Bioenergetics, ATP Generation, Redox Control, and Fatigue Resolution
2025 · Report
Neuro / cell-state / miRNA intelligence
Neuro systems integration, cell-state interpretation, miRNA logic, neuroplasticity context, and cell-fate intelligence surfaces.
Buyer fit: Neurotech, cell-atlas platforms, research institutions, precision-biology teams
Neuro cell integration dataset and framework
Public provenance record
miRNA Bio intelligence Vol 1
2025 · DOI-backed
miRNA Neuroplasticity OS – Volume II
Public provenance record
Reviewed pathway
Start with scope, then match the right commercial route.
A licensing request should identify the buyer type, domain of interest, intended use, access depth, commercial use case, AI requirements, and whether the discussion is evaluation, integration, licensing, partnership, or acquisition.
Request licensing reviewCommercial intelligence stack
BioAtlas packages biological topology into licensable graph intelligence.
Public pages show the commercial shape only. Protected workbenches, raw graph exports, full manifests, API access, embedding rights, model-training rights, sublicensing, exclusivity, and private deployment remain separate commercial rights.
Public boundary
This is a buyer-facing licensing surface. It does not expose internal dashboards, protected routes, raw datasets, patient-specific interpretation, diagnosis, prescribing, treatment guidance, or validated prediction claims.
Six-layer cell intelligence
Immune, neuroimmune, nervous-system, stress-response, and stem/progenitor signals mapped into identity/targeting, mechanism/threshold, ECS-GPCR-ligand, epigenetic/miRNA, therapeutics/protocols, and disease/clinical/biomarker navigation.
953 extracted records2,475 layer membershipspublic-safe summary only
Review access pathSystems/subsystems intelligence
Organ systems, subsystems, cells, organs, ECS overlays, PCD context, nervous atlas coverage, and systems-state interpretation packaged as governed navigation infrastructure.
immunenervousstress-responserepair/progenitor
Review access pathPCD six-layer intelligence
Programmed cell death mechanisms organised into governed layers for identity, mechanism, ECS/GPCR/ligand context, epigenetic/miRNA context, protocol references, and disease/biomarker navigation.
41 canonical PCDssix governed layersoncology subtype overlay
Review access pathPathway synergy graph
Target-pathway-synergy relationships transformed into strict UI-safe pathway cards, scored relationship summaries, and review-ready commercial lookup surfaces.
75,622 mined edges5,788 pathways76 strict pathway cards
Review access pathPharma intelligence graph
Therapeutic graph packaging for drug mechanisms, interaction context, route classes, compatibility layers, data/API rights, and diligence review pathways.
pharma graphroute classesdata/API licensing
Review access pathSovereign biomedical infrastructure
National and institutional licensing path for private deployment, controlled graph access, sovereign AI boundaries, support, data-rights separation, and strategic licensing.
national infrastructureprivate deploymentrights boundaries
Review access pathHallmark Systems Bridge
Where cancer hallmarks become graph intelligence.
BioAtlas connects oncology subtype mapping, canonical hallmark biology, six hallmark groups, six-layer databar actors, cryptic sequence topology, bioenergetic fields, tunnelling, entanglement, vibrational frequency, bioelectric resonance, and reviewed citation structure into one protected systems-intelligence layer.
Oncology entries
376
Canonical hallmarks
24
Hallmark groups
6
Overlay edges
9,024
Six-layer graph nodes
8,273
Six-layer graph edges
9,687
Tensor edges
8,326
Unified edge surface
27,037
Public boundary: this is research-navigation and systems annotation infrastructure. It is not diagnostic, prescribing, or validated clinical decision software.
BioAtlas Graph Value Stack
Three graph engines. One protected biomedical intelligence layer.
BioAtlas combines enzyme mechanism intelligence, metabolic topology, and hallmark systems mapping into protected graph infrastructure for research, licensing, clinical review support, and enterprise biomedical reasoning.
Enzyme intelligence
Enzyme candidates2,066
Relationship edges41,281
Graph leadersSIRT1 · DNMT1 · HDAC1
Metabolic intelligence
Graph nodes6,763
Graph edges8,575
Topology edges2,496
Hallmark intelligence
Oncology entries376
Overlay edges9,024
Unified edge surface27,037
Public boundary: this section describes platform architecture and graph coverage only. It does not expose raw protected datasets, clinical logic, workbook contents, or patient-specific recommendations.
Locked commercial review
Detailed licence routes are released after business review.
Public licensing shows the commercial architecture only. Detailed licence routes, pricing bands, graph modules, raw data rights, API terms, AI-use rights, exclusivity, private deployment, and diligence material are not displayed publicly.
Business email or institutional identity required
Use case, organisation, and rights scope reviewed first
Protected commercial pack released only after approval